Abstract
Recent years have witnessed EU markets updating their biosimilar policies; however, there remain countries where the full cost-savings potential of biosimilars is yet to be realized. This research aims to review the current EU biosimilar landscape, and to investigate the most recent policy shifts as an indicator of expected evolution in the post-COVID environment, as payers express growing interest in healthcare savings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
